公开(公告)号：US09500650B2

公开(公告)日：2016-11-22

申请号：US14355413

申请日：2012-10-31

申请人： National Institute of Advanced Industrial Science and Technology ,  Wako Pure Chemical Industries, Ltd.

发明人： Hiroaki Tateno ,  Jun Hirabayashi ,  Yuzuru Ito ,  Yasuko Onuma ,  Makoto Asashima ,  Atsushi Kuno ,  Masaki Warashina ,  Masakazu Fukuda

IPC分类号： G01N33/569 ,  C07K14/195

CPC分类号： G01N33/56966 ,  C07K14/195 ,  G01N2333/4724 ,  G01N2400/00

摘要： An object of the present invention is to provide a method for evaluating a differentiation status of cells using a culture supernatant of stem cells. Provided is “undifferentiation sugar chain marker” composed of the sugar chain structure “Fucα1-2Galβ1-3GlcNAc” or “Fucα1-2Galβ1-3GalNAc” and capable of sensitively determining the undifferentiated state of stem cells using a culture supernatant of stem cells. Also found is BC2LCN lectin or a modified product thereof capable of sensitively recognizing the “undifferentiation sugar chain marker” as excellent “probe for detecting the undifferentiation sugar chain marker” capable of determining the undifferentiation status of cells using a culture supernatant.

摘要翻译： 本发明的目的是提供一种使用干细胞的培养物上清液评估细胞分化状态的方法。 提供由糖链结构“Fucα1-2Galβ1-3GlcNAc”或“Fucα1-2Galβ1-3GalNAc”组成的能够使用干细胞的培养上清液敏感地测定干细胞的未分化状态的“未分化糖链标记”。 还发现BC2LCN凝集素或其能够敏感识别“未分化糖链标记”的优化“能够用培养上清液测定细胞未分化状态的”未分化糖链标志物的探针“的修饰产物。

公开(公告)号：US20150204870A1

公开(公告)日：2015-07-23

申请号：US14355413

申请日：2012-10-31

申请人： NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY ,  WAKO PURE CHEMICAL INDUSTRIES, LTD.

发明人： Hiroaki Tateno ,  Jun Hirabayashi ,  Yuzuru Ito ,  Yasuko Onuma ,  Makoto Asashima ,  Atsushi Kuno ,  Masaki Warashina ,  Masakazu Fukuda

IPC分类号： G01N33/569 ,  C07K14/195

CPC分类号： G01N33/56966 ,  C07K14/195 ,  G01N2333/4724 ,  G01N2400/00

摘要： An object of the present invention is to provide a method for evaluating a differentiation status of cells using a culture supernatant of stem cells. Provided is “undifferentiation sugar chain marker” composed of the sugar chain structure “Fucα1-2Galβ1-3GlcNAc” or “Fucα1-2Galβ1-3GalNAc” and capable of sensitively determining the undifferentiated state of stem cells using a culture supernatant of stem cells. Also found is BC2LCN lectin or a modified product thereof capable of sensitively recognizing the “undifferentiation sugar chain marker” as excellent “probe for detecting the undifferentiation sugar chain marker” capable of determining the undifferentiation status of cells using a culture supernatant.

摘要翻译： 本发明的目的是提供一种使用干细胞的培养物上清液评估细胞分化状态的方法。 提供由糖链结构“Fucα1-2Gal＆bgr; 1-3GlcNAc”或“Fucα1-2Gal＆bgr; 1-3GalNAc”组成的“未分化糖链标记”，其能够使用茎的培养物上清液敏感地测定干细胞的未分化状态 细胞。 还发现BC2LCN凝集素或其能够敏感识别“未分化糖链标记”的优化“能够用培养上清液测定细胞未分化状态的”未分化糖链标志物的探针“的修饰产物。

公开(公告)号：US20140057286A1

公开(公告)日：2014-02-27

申请号：US14051729

申请日：2013-10-11

申请人： Sysmex Corporation ,  National Center for Global Health and Medicine ,  Nagoya City University ,  National Institute of Advanced Industrial Science and Technology

发明人： Hisashi Narimatsu ,  Yuzuru Ikehara ,  Atsushi Kuno ,  Maki Sogabe ,  Yasuhito Tanaka ,  Masashi Mizokami ,  Kiyoaki Ito ,  Shunsuke Matsubara ,  Chikayuki Tsuruno ,  Youichi Takahama ,  Takashi Kagawa ,  Shinya Nagai

IPC分类号： G01N33/68

CPC分类号： G01N33/68 ,  C07K14/4726 ,  C07K14/473 ,  G01N33/5308 ,  G01N33/57438 ,  G01N33/6893 ,  G01N2333/4724 ,  G01N2333/4728 ,  G01N2400/00 ,  G01N2400/02 ,  G01N2800/085 ,  Y10T436/143333

摘要： An object of the present invention is to provide a method for measuring a glycan-marker glycoprotein, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Also, an object of the present invention is to provide a method for examining liver disease, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Also, an object of the present invention is to provide a reagent for quantitative determination of a glycoprotein, which is used for the above measurement methods. Furthermore, an object of the present invention is to provide a glycan-marker glycoprotein as an index for clinical conditions of liver disease, which is capable of identifying the clinical conditions of liver disease depending on the progress of liver disease. The method for measuring a glycoprotein is characterized in that: the glycoprotein is at least one glycoprotein selected from alpha-1-acid glycoprotein (AGP) and Mac-2-binding protein (M2BP) contained in a sample collected from a subject; when the glycoprotein is AGP, AGP binding to a first lectin selected from AOL and MAL is measured; and when the glycoprotein is M2BP, M2BP binding to a second lectin selected from WFA, BPL, AAL, RCA120, and TJAII is measured.

摘要翻译： 本发明的目的是提供一种测定聚糖标记糖蛋白的方法，通过该方法可以以比常规方法更高的精度检测肝脏疾病。 另外，本发明的目的在于提供一种检查肝脏疾病的方法，通过该方法能够以比常规方法更高的精度检测肝脏疾病。 另外，本发明的目的在于提供一种用于上述测定方法的糖蛋白定量试剂。 此外，本发明的目的是提供聚糖标记糖蛋白作为肝病临床病症的指标，其能够根据肝病的进展来鉴定肝脏疾病的临床状况。 测定糖蛋白的方法的特征在于：糖蛋白是从受试者收集的样品中含有的至少一种糖蛋白，其选自α-1-酸糖蛋白（AGP）和Mac-2结合蛋白（M2BP） 当糖蛋白为AGP时，测量与选自AOL和MAL的第一凝集素结合的AGP; 并且当糖蛋白为M2BP时，测量与选自WFA，BPL，AAL，RCA120和TJAII的第二凝集素结合的M2BP。

公开(公告)号：US20160187356A1

公开(公告)日：2016-06-30

申请号：US15071419

申请日：2016-03-16

申请人： National Institute of Advanced Industrial Science and Technology

发明人： Hisashi Narimatsu ,  Jun Hirabayashi ,  Atsushi Kuno ,  Hideki Matsuzaki ,  Yuzuru Ikehara ,  Hiromi Ito ,  Yasuhiro Hashimoto ,  Keiro Shirotani ,  Satoshi Futakawa ,  Hajime Arai ,  Masakazu Miyajima ,  Kazuo Fujihara

IPC分类号： G01N33/68 ,  H01J49/00

CPC分类号： G01N33/6896 ,  G01N33/6842 ,  G01N2333/47 ,  G01N2333/4728 ,  G01N2400/40 ,  G01N2800/285 ,  H01J49/0036

摘要： The purpose of the present invention is to develop: a method for selectively separating a glycoprotein derived from the central nervous system from a body fluid or a central nervous system cell; and a method for searching for an index marker for central nervous system diseases, which utilizes the aforementioned method. A protein derived from the central nervous system, which occurs in a trace amount in a body fluid or a central nervous system cell, can be selectively enriched by a two-stage separation procedure comprising removing a glycoprotein having sialic acid at a non-reducing terminal thereof from the body fluid or the central nervous system cell and then separating a glycoprotein having N-acetylglucosamine at a non-reducing terminal thereof.

摘要翻译： 本发明的目的是开发：从体液或中枢神经系统细胞中选择性分离衍生自中枢神经系统的糖蛋白的方法; 以及利用上述方法搜索中枢神经系统疾病指标的方法。 可以通过两步分离方法选择性地富集来自中枢神经系统的蛋白质，其在体液或中枢神经系统细胞中发生微量的蛋白质，其包括在非还原末端除去具有唾液酸的糖蛋白 从体液或中枢神经系统细胞中分离，然后在其非还原末端分离具有N-乙酰葡糖胺的糖蛋白。

公开(公告)号：US10539576B2

公开(公告)日：2020-01-21

申请号：US15620214

申请日：2017-06-12

申请人： National Institute of Advanced Industrial Science and Technology ,  Tokyo Medical University

发明人： Hisashi Narimatsu ,  Akira Togayachi ,  Yuzuru Ikehara ,  Hiroyuki Kaji ,  Atsushi Kuno ,  Takashi Ohkura ,  Hideki Matsuzaki ,  Yoshitoshi Hirao ,  Jun Iwaki ,  Minako Abe ,  Masaharu Nomura ,  Masayuki Noguchi

IPC分类号： G01N33/574 ,  G01N33/68 ,  C07K14/47 ,  C07K16/28 ,  C07K16/30

摘要： An object of the present invention is to develop and provide a lung cancer differential marker with which lung cancer can be diagnosed conveniently and highly sensitively without depending only on increase or decrease in protein expression level between cancer patients and healthy persons. Another object of the present invention is to develop and provide a glycan marker capable of distinguishing histological types of lung cancer. Of serum glycoproteins, glycopeptide and glycoprotein groups whose glycan structures were altered specifically in lung cancer cell culture supernatants were identified, and they are provided as lung cancer differential markers.

公开(公告)号：US10156576B2

公开(公告)日：2018-12-18

申请号：US15071419

申请日：2016-03-16

申请人： National Institute of Advanced Industrial Science and Technology

发明人： Hisashi Narimatsu ,  Jun Hirabayashi ,  Atsushi Kuno ,  Hideki Matsuzaki ,  Yuzuru Ikehara ,  Hiromi Ito ,  Yasuhiro Hashimoto ,  Keiro Shirotani ,  Satoshi Futakawa ,  Hajime Arai ,  Masakazu Miyajima ,  Kazuo Fujihara

IPC分类号： G01N33/68 ,  H01J49/00

摘要： The purpose of the present invention is to develop: a method for selectively separating a glycoprotein derived from the central nervous system from a body fluid or a central nervous system cell; and a method for searching for an index marker for central nervous system diseases, which utilizes the aforementioned method. A protein derived from the central nervous system, which occurs in a trace amount in a body fluid or a central nervous system cell, can be selectively enriched by a two-stage separation procedure comprising removing a glycoprotein having sialic acid at a non-reducing terminal thereof from the body fluid or the central nervous system cell and then separating a glycoprotein having N-acetylglucosamine at a non-reducing terminal thereof.

公开(公告)号：US10352927B2

公开(公告)日：2019-07-16

申请号：US14419804

申请日：2013-08-09

申请人： NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY

发明人： Hisashi Narimatsu ,  Atsushi Kuno ,  Yuzuru Ikehara ,  Yasuhiro Hashimoto ,  Keiro Shirotani ,  Kiyomitsu Nara ,  Yoshinobu Kariya ,  Hiromi Ito ,  Kyoka Hoshi

IPC分类号： G01N33/543 ,  G01N33/536 ,  G01N33/53 ,  G01N33/68

摘要： It is intended to develop and provide a method for detecting a particular glycan-isoform rapidly and specifically by a small number of steps. The present invention provides a glycan-isoform detection method comprising quantifying an immune complex formed by the mixing of a test sample with a sugar chain non-reducing terminal residue-binding lectin and an antibody specifically binding to the protein moiety of the glycan-isoform, etc., comparing the obtained amount of the immune complex with the amount of a control immune complex obtained when a control sample is not mixed with the sugar chain non-reducing terminal residue-binding lectin or is mixed with a control protein, and determining the presence or absence of the glycan-isoform of interest in the test sample on the basis of the difference between these amounts.

公开(公告)号：US20180106814A1

公开(公告)日：2018-04-19

申请号：US15809160

申请日：2017-11-10

申请人： SYSMEX CORPORATION ,  NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY ,  NAGOYA CITY UNIVERSITY ,  NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE

发明人： Hisashi Narimatsu ,  Yuzuru Ikehara ,  Atsushi Kuno ,  Maki Sogabe ,  Yasuhito Tanaka ,  Masashi Mizokami ,  Kiyoaki Ito ,  Shunsuke Matsubara ,  Chikayuki Tsuruno ,  Youichi Takahama ,  Takashi Kagawa ,  Shinya Nagai

IPC分类号： G01N33/68 ,  G01N33/574 ,  C07K14/47

CPC分类号： G01N33/68 ,  C07K14/4726 ,  C07K14/473 ,  G01N33/5308 ,  G01N33/57438 ,  G01N33/6893 ,  G01N2333/4724 ,  G01N2333/4728 ,  G01N2400/00 ,  G01N2400/02 ,  G01N2800/085 ,  Y10T436/143333

摘要： An object of the present invention is to provide a method for measuring a glycan-marker glycoprotein, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Also, an object of the present invention is to provide a method for examining liver disease, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Also, an object of the present invention is to provide a reagent for quantitative determination of a glycoprotein, which is used for the above measurement methods. Furthermore, an object of the present invention is to provide a glycan-marker glycoprotein as an index for clinical conditions of liver disease, which is capable of identifying the clinical conditions of liver disease depending on the progress of liver disease. The method for measuring a glycoprotein is characterized in that: the glycoprotein is at least one glycoprotein selected from alpha-1-acid glycoprotein (AGP) and Mac-2-binding protein (M2BP) contained in a sample collected from a subject; when the glycoprotein is AGP, AGP binding to a first lectin selected from AOL and MAL is measured; and when the glycoprotein is M2BP, M2BP binding to a second lectin selected from WFA, BPL, AAL, RCA120, and TJAII is measured.

公开(公告)号：US20170283506A1

公开(公告)日：2017-10-05

申请号：US15620214

申请日：2017-06-12

申请人： National Institute of Advanced Industrial Science and Technology ,  Tokyo Medical University

发明人： Hisashi Narimatsu ,  Akira Togayachi ,  Yuzuru Ikehara ,  Hiroyuki Kaji ,  Atsushi Kuno ,  Takashi Ohkura ,  Hideki Matsuzaki ,  Yoshitoshi Hirao ,  Jun Iwaki ,  Minako Abe ,  Masaharu Nomura ,  Masayuki Noguchi

IPC分类号： C07K16/30 ,  C07K14/47

摘要： An object of the present invention is to develop and provide a lung cancer differential marker with which lung cancer can be diagnosed conveniently and highly sensitively without depending only on increase or decrease in protein expression level between cancer patients and healthy persons. Another object of the present invention is to develop and provide a glycan marker capable of distinguishing histological types of lung cancer. Of serum glycoproteins, glycopeptide and glycoprotein groups whose glycan structures were altered specifically in lung cancer cell culture supernatants were identified, and they are provided as lung cancer differential markers.

公开(公告)号：US11571473B2

公开(公告)日：2023-02-07

申请号：US16972367

申请日：2019-06-06

申请人： NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY ,  UNIVERSITY OF TOYAMA

发明人： Hisashi Narimatsu ,  Kiyohiko Angata ,  Hiroyuki Kaji ,  Atsushi Kuno ,  Takashi Sato ,  Yasunori Chiba ,  Akira Togayachi ,  Hiroki Shimizu ,  Maki Sogabe ,  Takanori Wagatsuma ,  Masashi Mizokami ,  Masaaki Korenaga ,  Kazuto Tajiri ,  Tatsuhiko Ozawa

IPC分类号： A61K39/29 ,  C07K14/005 ,  A61P31/20 ,  C07K16/08 ,  G01N33/576 ,  A61K39/00

摘要： An examination system that recognizes a glycosylated antigen in Dane particles of hepatitis B virus (HBV) and a neutralizing antibody that recognizes the glycosylated antigen and that exhibits an infection-inhibiting activity. It was elucidated that Dane particles are associated with specific glycan structures, and this enabled the construction of a new detection system for infectious, i.e., nucleic acid-containing, hepatitis B virus particles and the provision of a neutralizing antibody that recognizes a glycosylated antigen and that exhibits an infection-inhibiting activity.